Menu

Blog

Apr 16, 2020

Gilead data suggests coronavirus patients are responding to treatment

Posted by in category: biotech/medical

A Chicago hospital treating severe COVID19 patients with Gilead Sciences’ antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.

Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests. The entire world has been waiting for results from Gilead’s clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies. If safe and effective, it could become the first approved treatment against the disease.


The outcomes in patients at a Chicago hospital offer only a snapshot of remdesivir’s effectiveness, but are the first clinical data to surface to date.

Leave a reply